Samarth Kulkarni, Chief Executive Officer and Director of CRISPR Therapeutics AG (NASDAQ:CRSP), filed a Form 4 on October 28, 2026, disclosing the acquisition of stock options and restricted stock units granted on October 26, 2026.

Key Highlights

  • Stock option grant: Kulkarni received options to purchase 57,500 Common Shares at an exercise price of $49.01, expiring October 26, 2036.
  • RSU grant: Kulkarni received 28,750 restricted stock units, each representing a contingent right to receive one Common Share.
  • Option vesting schedule: 100% of the 57,500 option shares vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
  • RSU vesting schedule: One quarter of the 28,750 RSUs vests on each of October 26, 2027, October 26, 2028, October 26, 2029, and October 26, 2030.
  • Price paid: Both the stock option and the RSU award were acquired at a price of $0, according to the filing.
  • Resulting holdings: Following the transactions, Kulkarni directly holds 57,500 derivative securities from the option grant and 28,750 derivative securities from the RSU grant.

Kulkarni's October 2026 Equity Award Details at CRISPR Therapeutics

According to the Form 4 filed October 28, 2026, Samarth Kulkarni, who serves as both Chief Executive Officer and Director of CRISPR Therapeutics AG (NASDAQ:CRSP), was granted two derivative security awards on October 26, 2026. The filing reports no transactions in Table I covering non-derivative securities. All reported activity appears in Table II covering derivative securities.

The first award is a stock option granting Kulkarni the right to purchase 57,500 Common Shares at $49.01 per share. The filing states the option expires on October 26, 2036, and that "100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026." Both awards are held directly, and the filing records the acquisition price for each as $0.

The second award is a restricted stock unit grant covering 28,750 Common Shares. The filing explains that each restricted stock unit "represents a contingent right to receive one share of CRSP Common Shares." Vesting is divided equally across four annual dates: one quarter on October 26, 2027; one quarter on October 26, 2028; one quarter on October 26, 2029; and one quarter on October 26, 2030. The Form 4 was signed by Elizabeth Ryland Waldinger as attorney-in-fact on October 28, 2026.

What Was Disclosed

The filing discloses two equity awards granted to CRISPR Therapeutics CEO Samarth Kulkarni on October 26, 2026: a stock option for 57,500 Common Shares at $49.01 vesting over 48 months, and 28,750 restricted stock units vesting in four equal annual installments through 2030.